DEA bans SR-17018, a compound showing promise in opioid withdrawal management

Why SR-17018 showed promise

Researchers at the University of South Florida Health identified SR-17018 as a compound capable of relieving pain in mice without causing respiratory depression—a common and often fatal side effect of traditional opioids like morphine. Unlike conventional treatments, mice given SR-17018 did not develop a high tolerance to the compound, and those already dependent on morphine could use it to reset their tolerance without experiencing severe withdrawal symptoms.

The findings suggested SR-17018 could offer a safer alternative for managing pain and reducing opioid dependence. Early anecdotal reports from individuals using the compound supported this potential. Two users, identified as Jim Bates and Michael, reported that SR-17018 helped them quit opioids without the prolonged dependence associated with treatments like buprenorphine and methadone.

DEA’s Schedule I classification

In August 2026, the Drug Enforcement Administration (DEA) classified SR-17018 as a Schedule I controlled substance, a category reserved for drugs deemed to have no accepted medical use and a high potential for abuse. The DEA’s decision cited limited samples of SR-17018 detected in two states since 2025 and concerns that the compound could lower opioid tolerance, potentially increasing overdose risks if users relapse.

The classification effectively halts further research into SR-17018 and restricts access for individuals relying on it to manage withdrawal. Researchers, including those at the University of South Florida Health, can no longer study the compound without navigating stringent regulatory hurdles.

Criticism and legal challenges

The DEA’s decision faced immediate backlash from advocates and legal experts. Robert Rush, an attorney and executive director of the Rights and Reason Project, filed a request to block the emergency scheduling, arguing that SR-17018 has a lower risk profile than other synthetic opioids the DEA has targeted. Rush described the move as "draconian," noting that the compound has not been linked to emergency room visits or overdose deaths. His request went unanswered by the DEA.

Critics also questioned the scientific basis for the ban. Michael, one of the users who relied on SR-17018, speculated that the compound may have been targeted because it threatened a multibillion-dollar addiction treatment industry built around long-term therapies like methadone and buprenorphine.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

The DEA’s classification of SR-17018 as a Schedule I substance reflects the tension between drug enforcement priorities and harm reduction efforts. For researchers and healthcare operators, this decision underscores the challenges of navigating regulatory barriers when exploring alternatives to traditional opioid treatments. The ban may slow innovation in addiction medicine and limit options for individuals seeking to break opioid dependence without long-term therapy.

For founders in the healthcare or biotech sectors, the story highlights the risks of developing compounds that could disrupt established treatment models. Regulatory scrutiny may intensify for drugs perceived as threats to existing markets, even if they show promise in addressing unmet medical needs.

Related on Lazyfounder

• US Food and Drug Administration
• More health news